Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of evinacumab in refractory hypercholesterolemia in Japan
jRCT2080224063Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals, Inc. (Clinical Trial In-Country Representative:PAREXEL International)
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in familial hypercholesterolemia (FH), hypercholesterolemia and atherosclerotic disease comparing Evinacumab arm with Placebo arm (2 arms). Primary endpoint: LDL cholesterol reduction. Started Aug 2018; status: completed.
02
Drugs
evinacumab
03
Conditions
familial hypercholesterolemia (FH)hypercholesterolemiaatherosclerotic disease
Beyond the preview
Go deeper on jRCT2080224063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224063.